Arbutus Biopharma Corp., of Vancouver, British Columbia, reported results from the multiple-dose cohort of its ongoing phase II study of RNAi candidate ARB-1467 in chronically infected hepatitis B virus (HBV) patients on stable nucleotide/nucleoside therapy, showing a significant reduction of HBsAg.